Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Clearmind Medicine Inc (OP: CMNDF ) N/A UNCHANGED Last Price Updated: 10:24 AM EST, Nov 11, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Clearmind Medicine Inc This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split November 15, 2022 Psychedelics biotech firm Clearmind Medicine Inc. Via Benzinga Clearmind Medicine Announces Pricing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market November 14, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV October 11, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements September 26, 2022 In connection with recent stock splits, psychedelics biotech Clearmind Medicine Inc. Via Benzinga SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc. June 07, 2022 SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addiction Via Benzinga SciSparc And Clearmind Partnership Yields 3rd Patent Application For The Treating Of Obesity And Metabolic Syndromes September 22, 2022 SciSparc Ltd. (NASDAQ: SPRC) announced that Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0), has filed a provisional patent application related to metabolic syndromes including obesity,... Via Benzinga Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration August 25, 2022 SciSparc Ltd. (NASDAQ: SPRC) recently announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel... Via Benzinga SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc. August 25, 2022 Results indicate significant decrease in cocaine craving in a sub-group that received the treatment Via Benzinga Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know August 24, 2022 Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd. Via Benzinga Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies June 08, 2022 The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs. Via Benzinga The Bad And The Ugly? The State Of Excessive Alcohol Consumption In The U.S. June 08, 2022 Photo by LauritaM on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Via Benzinga Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics June 07, 2022 Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still... Via FinancialNewsMedia Exposures COVID-19 SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction June 02, 2022 SciSparc Ltd. (NASDAQ: SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine... Via Benzinga SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction June 02, 2022 No dedicated treatment currently available for cocaine addiction Via Benzinga New Psychedelic-Based Alcohol Substitute Approved In India, Produced By Clearmind Medicine June 01, 2022 India's Office of the Controller-General of Patents, Designs and Trademarks granted approval for a new compound created by the biotech company Clearmind Medicine Inc. (OTC Pink: CMNDF). Via Benzinga High Hopes For Alcohol Use Disorder Treatment: Clearmind's Successful Pre-IND Meeting With The FDA May 26, 2022 The meeting, which took place on May 18 between the psychedelic pharmaceutical biotech company Clearmind Medicine Inc. (CMNDF) and the US Food and Drug Administration marks the completion the pre-IND... Via Benzinga Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company May 24, 2022 Medical Psychedelics have made it into Davos, just in time for the World Economic Forum. Via Benzinga Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results May 24, 2022 Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems,... Via Benzinga Global Psychedelics Market Is Expected To Reach $8 Billion By 2029 May 24, 2022 Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster... Via FinancialNewsMedia Clearmind: Positive Preclinical Evidence For Flagship Psychedelic Molecule, Looks To Human Trials Before Year End May 19, 2022 Psychedelics biotech company Clearmind Medicine Inc. Via Benzinga Psyched: Compass, Atai And MindMed Release Q1 Earnings, Phase 3 MDMA Trial Closer To Completion, Enveric Splits Into Two Companies May 17, 2022 The psychedelics space got a new glimpse at the financials of some of its heavy hitters with the release of earnings reports for the first quarter of 2022. Via Benzinga Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested May 13, 2022 On Wednesday, May 18, Clearmind Medicine Inc. (OTC Pink: CMNDF) will meet with the Center for Drug Evaluation and Research (CDER), a department within the FDA. Via Benzinga SciSparc And Clearmind Reveal Potential To Reduce Alcohol Consumption With Psychedelic Treatment In New Patent Application May 11, 2022 Image by Thom Masat on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga SciSparc And Clearmind Medicine Inc. Collaboration Yields New Patent Application For Psychedelic Combination Treatment For Binge Behaviors May 10, 2022 Preclinical study results demonstrated the combination of SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption Via Benzinga Alcoholism & Psychedelics: Clearmind Trials Reveal Certain Psychedelics Help Reduce Alcohol Consumption In Mice March 17, 2022 Clearmind Medicine Inc. Via Benzinga Clearmind Medicine, SciSparc Launch A Psychedelic Pharma Collaboration March 08, 2022 Psychedelic-focused biotech company Clearmind Medicine Inc. (CSE:CMND) (OTC: CMNDF) has signed a collaboration agreement with ... Via Benzinga InvestorNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) to Host Third Event in Psychedelics for Alcoholism Series February 01, 2022 Via Investor Brand Network BioMedNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) Partners with Renowned Expert to Discuss Alcohol Use Disorder and Trauma at Upcoming Virtual Event January 31, 2022 Via Investor Brand Network InvestorNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) Announces Featured Speaker for Psychedelics for Alcoholism series January 27, 2022 Via Investor Brand Network Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.